Physician profile
Astrid Gutsmann
NPI 1003851676
$2,734.63
in general payments reported to CMS, 2019-2025
28 companies · $783 in 2025
The $783 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2020: $218 · 2021: $297 · 2022: $446 · 2023: $366 · 2024: $115 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $460.35 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $379.81 | 2019-2025 | Zepbound, Mounjaro |
| Amgen INC. | $358.25 | 2019-2023 | Prolia, Evenity |
| Abbvie INC. | $224.54 | 2021-2023 | |
| Corcept Therapeutics | $155.76 | 2025 | Korlym |
| Allergan, INC. | $155.30 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $146.27 | 2022-2025 | Farxiga |
| Novo Nordisk INC | $143.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $87.05 | 2019-2022 | |
| Verity Pharmaceuticals INC. | $66.69 | 2024-2025 | Tlando |
| Pfizer INC. | $64.14 | 2020-2025 | |
| Dexcom, INC. | $62.62 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $55.69 | 2019-2021 | |
| Gilead Sciences, INC. | $52.55 | 2019 | |
| Antares Pharma, INC. | $48.63 | 2025 | Xyosted |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $34.42 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $29.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.53 | 2019-2020 | |
| Axsome Therapeutics, INC. | $25.40 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company LTD. | $23.26 | 2022 | |
| Si-Bone, INC. | $16.48 | 2019 | |
| Acella Pharmaceuticals, LLC | $16.39 | 2023 | NP Thyroid 60 |
| Medtronic USA, INC. | $16.02 | 2019 | |
| Ibsa Pharma INC. | $14.83 | 2021 | |
| Insulet Corporation | $12.86 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.29 | 2022 | |
| Genentech USA, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Astrid Gutsmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.